NEWS ARTICLE
Challenging the Logic of Cost Effectiveness
«A Critical Analysis of the History and Impact of Cost Effectiveness Thresholds (CETs) - Emerging Lessons and Insights for Decision-Makers»:
Health Technology Assessments (HTAs) typically rest primarily on one or two pillars. An assessment of comparative clinical effectiveness may be followed by a comparative economic evaluation, which usually takes the form of a cost effectiveness analysis with life years gained or quality-adjusted life years – QALYs – gained as a putatively universal and comprehensive measure of benefit (predominantly in Europe sometimes called «cost utility analysis», CUA). To be useful across a broad range of therapeutic areas, there is a need for a benchmark or «cut-off» level – the «cost effectiveness threshold» (or «CET»). It separates cost effective and not cost effective health care programs. However, both the use as well as the value of these CETs is controversial and varies across jurisdictions. Few (if any) HTA agencies have adopted the undelying logic of cost effectiveness without modifications – and a number of HTA agencies have explicitly rejected the use of CETs – or even the use of cost effectiveness altogether.
At the European ISPOR 2026 Congress in Vienna, Austria, Michael Schlander offered an overview of emerging findings from an ongoing project to critically assess the use and limitations of CETs to inform decisions on health care coverage, notably the access to new medicines. He concluded that there are fundamental unresolved issues directly linked to the use of CETs to inform decisions on access to medical treatments. There are situations in which they may result in positively unethical conclusions, unless one is prepared to accept a highly reductionist, quasi-act utilitarian perspective, which is difficult to align with European rights-based constitutional traditions and the objectives of collectively financed health schemes. The issues exceed the historic experience with CETs, the lack of an uncontroversial scientific basis to determine their possible dimension, and a host of complex ethical and empirical problems. Given the far-reaching consequences for patients and their access to health care, international health care policymakers appear to be well-advised to exercise great caution before implementing an approach relying on any simple benchmark for cost effectiveness.
The presentation to ISPOR on November 11, 2026, can be found here.